Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
| Image |  |
|---|---|
| Description | scientific article published on 07 April 2020 |
| Author/s |
author: Michael Robert Savona Jianxiang Wang Giuseppe Saglio |
| Publication date | April 7, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |